“We are grateful to INCa for funding our project NeoPREDICT: A multicentric phase II trial to personalize neoadjuvant chemotherapy for patients with borderline resectable pancreatic adenocarcinoma using the Pancreas View signature.”
Scientific Director of the company Predicting Med (CSO) and Chair of TRANSLATE-IT CRCM. He is also research director at INSERM. He is the Head of the Department of Translational Research and Innovative Therapies at CRCM.